BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3081996)

  • 1. Aspirin does not inhibit human megakaryocyte thromboxane synthesis in vivo.
    Huijgens PC; van den Berg CA; Imandt LM; Miltenburg A; Langenhuijsen MM
    Scand J Haematol; 1986 Jan; 36(1):92-5. PubMed ID: 3081996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of aspirin on human megakaryocyte prostaglandin synthesis.
    van Pampus EC; Huijgens PC; Zevenbergen A; Twaalfhoven H; van Kamp GJ; Langenhuijsen MM
    Eur J Haematol; 1993 May; 50(5):264-8. PubMed ID: 8319788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin inhibits rat megakaryocyte thromboxane synthesis.
    Worthington RE; Nakeff A
    Prostaglandins; 1982 Jun; 23(6):841-53. PubMed ID: 6812167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of megakaryocyte thromboxane production in vitro after aspirin inhibition.
    Walenga RW; Miller JL; Stuart MJ
    Biochem Biophys Res Commun; 1984 Mar; 119(3):982-8. PubMed ID: 6712680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin.
    Rao GH; Johnson GG; Reddy KR; White JG
    Arteriosclerosis; 1983; 3(4):383-8. PubMed ID: 6411052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired thromboxane production by newly formed platelets after aspirin administration to thrombocytopenic rats.
    Dejana E; Barbieri B; Cerletti C; Livio M; de Gaetano G
    Br J Haematol; 1980 Nov; 46(3):465-9. PubMed ID: 7448129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of platelet cyclooxygenase by aspirin-like drugs: methods for in vitro and ex vivo assessment.
    Patrono C; Ciabattoni G; Pugliese F; Pinca E; Castrucci G; De Salvo A; Satta MA; Parachini M
    Agents Actions Suppl; 1979; (4):138-46. PubMed ID: 115255
    [No Abstract]   [Full Text] [Related]  

  • 8. Triflusal vs aspirin on the inhibition of human platelet and vascular cyclooxygenase.
    de la Cruz JP; Mata JM; Sanchez de la Cuesta F
    Gen Pharmacol; 1992 Mar; 23(2):297-300. PubMed ID: 1639242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of platelet cyclooxygenase inhibition.
    Patrono C; Ciabattoni G; Patrignani P; Pugliese F; Filabozzi P; Catella F; Davì G; Forni L
    Circulation; 1985 Dec; 72(6):1177-84. PubMed ID: 3933848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential inhibition by aspirin of platelet thromboxane and renal prostaglandins in the rat.
    Livio M; Benigni A; Zoja C; Begnis R; Morelli C; Rossini M; Garattini S; Remuzzi G
    J Pharmacol Exp Ther; 1989 Jan; 248(1):334-41. PubMed ID: 2492341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salicylamide reverses the aspirin-antagonistic effect of salicylic acid on rat platelet cyclooxygenase.
    Rizk M; Abdel-Rahman MS
    Prostaglandins Leukot Essent Fatty Acids; 1994 Nov; 51(5):363-7. PubMed ID: 7846108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent inhibition of platelet cyclooxygenase by indomethacin is slowly reversible.
    Walenga RW; Wall SF; Setty BN; Stuart MJ
    Prostaglandins; 1986 Apr; 31(4):625-37. PubMed ID: 3088675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enteric-coated aspirin, platelet cyclooxygenase activity and function.
    Rao GH; Radh E; Johnson GJ; White JG
    Prostaglandins Leukot Med; 1984 Mar; 13(3):341-7. PubMed ID: 6425869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Megakaryocyte thromboxane production induced by platelet stimuli during in vitro culture.
    Walenga RW; Miller JL; Stuart MJ
    Exp Hematol; 1985 Feb; 13(2):87-91. PubMed ID: 3918879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration.
    Martin JF; Trowbridge EA; Salmon G; Plumb J
    Thromb Res; 1983 Dec; 32(5):443-60. PubMed ID: 6658722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase.
    Pedersen AK; FitzGerald GA
    N Engl J Med; 1984 Nov; 311(19):1206-11. PubMed ID: 6436696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet adhesivity to subendothelium is influenced by polymorphonuclear leukocytes: studies with aspirin and salicylate.
    Hernández R; Alemany M; Bozzo J; Buchanan MR; Ordinas A; Bastida E
    Haemostasis; 1993; 23(1):1-7. PubMed ID: 8477903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease.
    Sciulli MG; Renda G; Capone ML; Tacconelli S; Ricciotti E; Manarini S; Evangelista V; Rebuzzi A; Patrignani P
    Clin Pharmacol Ther; 2006 Aug; 80(2):115-25. PubMed ID: 16890573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose effect of enteric-coated aspirin on platelet function and thromboxane generation in middle-aged men.
    Mohri H; Ohkubo T
    Ann Pharmacother; 1993 Apr; 27(4):405-10. PubMed ID: 8477113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.